Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Capital Expenditures (2021 - 2025)

Krystal Biotech (KRYS) has disclosed Capital Expenditures for 5 consecutive years, with $2.4 million as the latest value for Q4 2025.

  • Quarterly Capital Expenditures fell 51.7% to $2.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.1 million through Dec 2025, down 63.9% year-over-year, with the annual reading at $3.1 million for FY2025, 63.9% down from the prior year.
  • Capital Expenditures hit $2.4 million in Q4 2025 for Krystal Biotech, up from -$7.5 million in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $45.1 million in Q4 2021 to a low of -$32.8 million in Q4 2022.
  • Historically, Capital Expenditures has averaged $5.3 million across 5 years, with a median of $3.2 million in 2021.
  • Biggest five-year swings in Capital Expenditures: surged 896.19% in 2024 and later crashed 815.58% in 2025.
  • Year by year, Capital Expenditures stood at $45.1 million in 2021, then plummeted by 172.77% to -$32.8 million in 2022, then soared by 102.12% to $696000.0 in 2023, then skyrocketed by 627.01% to $5.1 million in 2024, then plummeted by 51.7% to $2.4 million in 2025.
  • Business Quant data shows Capital Expenditures for KRYS at $2.4 million in Q4 2025, -$7.5 million in Q3 2025, and $6.7 million in Q2 2025.